What is Leerink Partnrs' Forecast for Exelixis Q2 Earnings?

Key Points

• Leerink Partners has revised its Q2 2025 earnings estimate for Exelixis, increasing the expected earnings per share (EPS) from $0.61 to $0.63.
• Exelixis reported a Q2 earnings of $0.75 per share, exceeding analysts' expectations of $0.63, though revenue fell short at $568.26 million against the anticipated $574.36 million.
• Multiple brokerages have recently updated their ratings and price targets for Exelixis, with Jefferies setting a target price of $50.00 and Stephens upgrading to an "overweight" rating with a target of $60.00.

Exelixis, Inc. (NASDAQ:EXEL - Free Report) - Equities researchers at Leerink Partnrs boosted their Q2 2025 earnings estimates for shares of Exelixis in a research report issued on Saturday, July 26th. Leerink Partnrs analyst A. Berens now expects that the biotechnology company will earn $0.63 per share for the quarter, up from their prior estimate of $0.61. The consensus estimate for Exelixis' current full-year earnings is $2.04 per share. Leerink Partnrs also issued estimates for Exelixis' Q3 2025 earnings at $0.68 EPS, FY2025 earnings at $2.61 EPS and FY2026 earnings at $2.95 EPS.

Several other research analysts have also recently commented on EXEL. Bank of America upped their target price on shares of Exelixis from $45.00 to $46.00 and gave the stock a "neutral" rating in a research report on Thursday, June 5th. Wall Street Zen cut shares of Exelixis from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 15th. Jefferies Financial Group set a $50.00 target price on shares of Exelixis and gave the stock a "buy" rating in a report on Tuesday, June 24th. Stifel Nicolaus raised their target price on shares of Exelixis from $38.00 to $41.00 and gave the stock a "hold" rating in a report on Tuesday. Finally, Royal Bank Of Canada reduced their target price on shares of Exelixis from $50.00 to $45.00 and set a "sector perform" rating for the company in a report on Tuesday. One research analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $44.44.

Exelixis Trading Up 2.9%

EXEL traded up $1.04 on Tuesday, hitting $37.26. 5,610,638 shares of the company's stock were exchanged, compared to its average volume of 3,086,219. The firm has a market cap of $10.03 billion, a PE ratio of 17.91, a P/E/G ratio of 0.74 and a beta of 0.28. Exelixis has a twelve month low of $23.21 and a twelve month high of $49.62. The stock has a fifty day moving average of $43.03 and a two-hundred day moving average of $38.89.

Exelixis (NASDAQ:EXEL - Get Free Report) last issued its earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.63 by $0.12. The business had revenue of $568.26 million for the quarter, compared to analyst estimates of $574.36 million. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The company's revenue for the quarter was down 10.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.84 EPS.

Insider Buying and Selling at Exelixis

In other news, CMO Amy C. Peterson sold 72,776 shares of the firm's stock in a transaction on Friday, May 16th. The shares were sold at an average price of $45.47, for a total transaction of $3,309,124.72. Following the transaction, the chief marketing officer owned 465,393 shares in the company, valued at approximately $21,161,419.71. This trade represents a 13.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jeffrey Hessekiel sold 25,000 shares of the firm's stock in a transaction on Thursday, May 15th. The shares were sold at an average price of $46.18, for a total transaction of $1,154,500.00. Following the completion of the transaction, the executive vice president owned 693,396 shares in the company, valued at $32,021,027.28. The trade was a 3.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 456,605 shares of company stock worth $20,966,005 in the last ninety days. Company insiders own 2.82% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of EXEL. GAMMA Investing LLC grew its position in Exelixis by 32.2% in the 1st quarter. GAMMA Investing LLC now owns 5,457 shares of the biotechnology company's stock worth $201,000 after purchasing an additional 1,328 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Exelixis during the 4th quarter valued at about $17,046,000. Wells Fargo & Company MN boosted its position in shares of Exelixis by 1,637.9% during the 4th quarter. Wells Fargo & Company MN now owns 746,286 shares of the biotechnology company's stock valued at $24,851,000 after acquiring an additional 703,343 shares in the last quarter. Park Avenue Securities LLC boosted its position in shares of Exelixis by 10.6% during the 1st quarter. Park Avenue Securities LLC now owns 7,358 shares of the biotechnology company's stock valued at $272,000 after acquiring an additional 707 shares in the last quarter. Finally, Envestnet Asset Management Inc. boosted its position in shares of Exelixis by 23.9% during the 1st quarter. Envestnet Asset Management Inc. now owns 248,073 shares of the biotechnology company's stock valued at $9,159,000 after acquiring an additional 47,845 shares in the last quarter. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.